Nuvectis Pharma, Inc.
NVCTNasdaq
$19.14
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↑ +134.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$448.2M
Enterprise Value
$423.0M
P/E
—
P/S
—
P/B
31.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$27.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-191.0%
ROIC
—
Debt / Equity
—
Net Cash
$25.1M
Return 1Y
+140.8%
Company profile
Nuvectis Pharma focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
- CEO
- Ronald E. Bentsur
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Headquarters
- New Jersey
- Website
- nuvectis.com
Management & directors
- Bentsur RonChairman & CEO
- Carson Michael J.Vice President, Finance
- Poradosu EnriqueChief Science & Business Off
- Shemesh ShayChief Dev. & Ops. Officer
Roles derived from SEC Form 4 filings.
Earnings
NVCT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.26↓ -3.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M |
| Net income | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Diluted EPS | -$3.02 | -$1.51 | -$1.43 | -$1.11 | -$1.32 |
| Operating cash flow | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.6M | -$4.4M | -$6.4M | -$5.6M | -$6.6M | -$7.8M | -$7.6M | -$6.3M |
| Net income | -$4.4M | -$4.2M | -$6.2M | -$5.3M | -$6.3M | -$7.5M | -$7.3M | -$6.0M |
| Diluted EPS | -$0.26 | -$0.24 | -$0.36 | -$0.27 | -$0.30 | -$0.44 | -$0.31 | -$0.26 |
| Operating cash flow | -$3.0M | -$2.4M | -$2.5M | -$4.2M | -$3.4M | -$4.5M | -$4.0M | -$6.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 1, 2026
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Mosseri Marlio Charles | Buy | 50,000 | $18.32 | $916,000.00 | filing |
| 2026-06-30 | BENTSUR RON· Chairman & CEO | Buy | 12,500 | $20.00 | $250,000.00 | filing |
| 2026-06-11 | Hoberman Kenneth | Award | 35,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Oliviero James F III | Award | 35,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Sanchez Juan | Award | 35,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Kaplan Matthew L. | Award | 35,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Shemesh Shay· Chief Dev. & Ops. Officer | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | BENTSUR RON· Chairman & CEO | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Poradosu Enrique· Chief Science & Business Off | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Carson Michael J.· Vice President, Finance | Award | 61,200 | $0.00 | $0.00 | filing |
| 2025-11-05 | Sanchez Juan | Buy | 13,000 | $5.79 | $75,270.00 | filing |
| 2025-11-05 | Kaplan Matthew L. | Buy | 11,000 | $5.84 | $64,240.00 | filing |
| 2025-11-05 | BENTSUR RON· Chairman & CEO | Buy | 5,000 | $5.72 | $28,600.00 | filing |
| 2025-10-27 | Mosseri Marlio Charles | Buy | 72,836 | $6.28 | $457,410.08 | filing |
| 2025-10-24 | Mosseri Marlio Charles | Buy | 35,034 | $6.15 | $215,459.10 | filing |
| 2025-10-23 | Mosseri Marlio Charles | Buy | 46,900 | $6.06 | $284,214.00 | filing |
| 2025-09-22 | Sanchez Juan | Award | 30,000 | $0.00 | $0.00 | filing |
| 2025-06-20 | Mosseri Marlio Charles | Buy | 5,603 | $7.99 | $44,767.97 | filing |
| 2025-06-18 | Mosseri Marlio Charles | Buy | 28,043 | $8.05 | $225,746.15 | filing |
| 2025-06-17 | Mosseri Marlio Charles | Buy | 5,399 | $8.11 | $43,785.89 | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.